Aerobic activity, even below recommended level, was linked to lower mortality, while a J-shaped pattern was seen for muscle-strengthening activity.
Flu-related hospitalization rates higher for indigenous people
Apr 14, 2023
The pooled mortality rate ratio was 3.3 in the United States.
COVID-19 hospitalization tied to higher death rate than the flu
Apr 11, 2023
The findings were seen among those hospitalized in the VA health system during the 2022-2023 flu season.
Electronic reminders boost flu vaccine uptake in older adults
Mar 22, 2023
Letters highlighting the potential cardiovascular benefits of influenza vaccination were found to be particularly effective.
Flu vaccine effective for 2022/2023 season
Feb 27, 2023
Vaccine effectiveness was 54% against medically attended outpatient acute respiratory infection associated with influenza A in patients younger than 65 years.
FDA approves first home test to detect both flu and COVID-19
Feb 27, 2023
The test will be sold without a prescription and can be used by anyone 14 years and older or by an adult on children ages 2 years and older.
Recommended 2023 adult immunization schedule published
Feb 10, 2023
Changes include a new section relating to COVID-19 vaccines and the addition of a newly licensed vaccine for hepatitis B.
New CDC respiratory disease dashboards provide senior living with early warning system
By
Kimberly Bonvissuto
Jan 20, 2023
Two new respiratory disease dashboards released by the Centers for Disease Control and Prevention can provide senior living operators with an early warning system to prepare against viruses circulating...
COVID-19 deaths preventable if available tools used: expert
By
Kimberly Bonvissuto
Jan 10, 2023
Most deaths attributable to COVID-19 today are preventable through the use of tools including vaccines, quality face masks and antiviral treatments, according to a special pathogens expert.
Flu vaccine 36 percent effective against A(H3N2) in 2021/2022
Jan 03, 2023
All sequenced A(H3N2) viruses belonged to genetic group 3C.2a1b subclade 2a.2, which was antigenically different from 2021-2022 vaccine component.